Neuland Laboratories reported a significant surge in its financial performance for Q2FY26, with total income reaching ₹516.1 crore and EBITDA soaring to ₹156.9 crore. This growth was primarily driven by strong commercial projects in CMS. The company anticipates continued momentum throughout the rest of the year and is well-positioned to leverage growth opportunities in both CDMO and generic APIs.
Exceptional Revenue Growth
Neuland Laboratories (NSE: NEULANDLAB; BSE:524558) announced its financial results for the half-year ended September 30, 2025, showcasing substantial growth in key financial metrics. The company’s total income for Q2FY26 reached ₹516.1 crore, while EBITDA stood at ₹156.9 crore.
Management Commentary
Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer, commented on the performance, stating that the record high revenue this quarter was driven by CMS commercial projects. He added, “The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.”
Mr. Saharsh Davuluri, Vice Chairman and Managing Director, added, “Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.”
Key Financial Highlights
Below is a summary of the financial results (₹ in crores):
Source: BSE
